Shanghai releases three major action plans in the field of biopharmaceuticals, with nearly 5 million square meters of factory buildings to be built

Shanghai, which has listed biopharmaceuticals as one of the three leading industries, has also released new industrial policies.At the opening ceremony of the 2023 Shanghai International Biomedical Industry Week held on the afternoon of the 16th, Shanghai released three major action plans for the three cutting-edge tracks of synthetic biology, gene therapy, and medical robotics

Shanghai, which has listed biopharmaceuticals as one of the three leading industries, has also released new industrial policies.

At the opening ceremony of the 2023 Shanghai International Biomedical Industry Week held on the afternoon of the 16th, Shanghai released three major action plans for the three cutting-edge tracks of synthetic biology, gene therapy, and medical robotics.

The Action Plan for Shanghai to Accelerate the Innovation of Synthetic Biotechnology and Build a High end Biomanufacturing Industry Cluster (2023-2025) captures the new wave of global bioeconomic transformation, and regards synthetic biotechnology as an important engine for the development of Shanghai's high-end manufacturing industry; The Shanghai Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development (2023-2025) is committed to breaking through key core technologies of gene therapy, improving clinical research and transformation capabilities, promoting production process progress, optimizing industrial development ecology, and comprehensively enhancing Shanghai's gene therapy technology innovation policy capacity and industrial development level; The Shanghai Action Plan for Promoting the Development of the Medical Robot Industry (2023-2025) is forming an innovative system that integrates industry and medicine, drives digital intelligence, and is open and leading, creating a batch of domestically leading and even internationally advanced innovative medical robot products.

In addition, in order to showcase the overall situation of the digital transformation of the biopharmaceutical industry, the China Academy of Information and Communications, in collaboration with the Shanghai Biomedical Industry Promotion Center, the Shanghai Biomedical Industry Association Biomedical Digitalization Special Committee, and other units, jointly developed the "2023 Global Biomedical Industry Digital Transformation Ecological Map".

This graph system outlines the entire digital transformation of the biopharmaceutical industry, showcasing six core applications, four industry platforms, and some representative enterprises of six key technologies. The six core applications cover key areas of research and development, production, supply chain, marketing, quality control, and management. The four major industrial platforms include data platforms, cloud platforms, industrial internet platforms, and artificial intelligence platforms. The six underlying technologies include big data, the Internet of Things, data twins, hybrid reality, blockchain, and 5G.

In 1993, Shanghai listed the modern biology and medicine industry as a key high-tech industry for development. Over the past 30 years, the Shanghai biopharmaceutical industry has grown from an industrial output value of less than 5 billion yuan to an industrial output value of nearly 200 billion yuan and an industrial scale of nearly 900 billion yuan, and has been growing by over 100 billion yuan for three consecutive years. In order to create a "tropical rainforest" like biopharmaceutical industry ecosystem, what other areas do we need to focus on?

Liu Ping, Deputy Director of the Shanghai Municipal Commission of Economy and Information Technology, previously introduced that first-class industrial ecology is a solid guarantee for the development of the biopharmaceutical industry. Shanghai will strengthen forward-looking planning, target high-end, intelligent, and international directions, actively promote the deep integration of the "five chains" of innovation, industry, capital, talent, and space, and strive to create a "tropical rainforest" like ecosystem for the development of the biopharmaceutical industry.

Golden Leaf/Photo

At the opening ceremony, the "Shanghai Action Plan for Accelerating the Construction of Biomedical Intelligent Manufacturing Space" was officially released, which will further strengthen the spatial guarantee for the development of Shanghai's biopharmaceutical industry and help enterprises seize industrial development opportunities.

According to this plan, in the next two years, the entire city of Shanghai will commence construction of biopharmaceutical standard factories with a total scale of nearly 5 million square meters, forming a new system of biopharmaceutical "incubation research and development pilot scale industrialization" cascade industrial carriers, and creating a new highland for global biopharmaceutical research and development economy and industrialization. The plan will also support development entities such as Lingang, Zhangjiang, and Waigaoqiao to carry out the construction of biopharmaceutical intelligent manufacturing spaces, and find the "smart high point" of high-end manufacturing in Shanghai's biopharmaceutical industry.

Liu Ping previously revealed at a press conference that Shanghai will continue to build a "1+5+x" industrial spatial pattern led by Zhangjiang, promote the "Intelligent Manufacturing Space Construction Action Plan", and orderly commence the construction of nearly 5 million square meters of biopharmaceutical standard factories, of which approximately 1.8 million square meters will be started in 2023. While strengthening the improvement of original innovation capabilities and breakthroughs in key core technologies, we aim to achieve high-quality achievement transformation, forward-looking emerging industry leadership, and high-quality ecological construction. By overlapping policies at the city and district levels, a spatial pattern of complementary industrial characteristics is formed in each district.

In addition to the release of policy measures, this Industrial Week will also hold overseas branch events for the first time. On the tenth anniversary of the "the Belt and Road" initiative, Shanghai organized representatives of 20 institutions of higher learning and benchmark enterprises, including Shanghai Jiaotong University School of Medicine and Shanghai University of Technology, to go to Bishkek, the capital of Kyrgyzstan, and then visited Kazakhstan to teach Chinese medical experience and products locally.

Fan Xianqun, an academician of the CAE Member, dean of the School of Medicine of Shanghai Jiaotong University, and an ophthalmologist, told the media, including First Finance, that Shanghai is the top in clinical medicine and medical technology in China. Although Shanghai is the home city of this industry week, it will also go to Central Asia to promote Shanghai's advanced technology and equipment in the pharmaceutical industry, as well as the latest diagnostic and treatment results. According to the Medical College of Shanghai Jiao Tong University, during this visit, they will dispatch 5 ophthalmologists to conduct ophthalmic diagnosis and treatment lectures in medical institutions in Kazakhstan and Kyrgyzstan, and demonstrate 6 surgeries locally.

Cheng Yunzhang, secretary-general of the the Belt and Road Medical Device Innovation and Application Alliance and dean of the School of Medical Devices of Shanghai University of Technology, said in an interview with First Finance on the afternoon of 16th that they had several specific tasks for this trip, including the demonstration of representative enterprises in Shanghai on the other side of Kyrgyzstan, and the signing of talent training cooperation agreements with several local medical schools from the perspective of talent training. The third issue is how to promote Shanghai's innovative medical device products to Central Asian countries, as many Central Asian countries still have a certain gap in their medical device products compared to ours. We happen to have this opportunity to go abroad

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])